COMPUTED DESCRIPTORS
| Molecular Weight | 591.5 g/mol |
|---|---|
| XLogP3 | 2.5 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 7 |
| Exact Mass | 591.20172853 g/mol |
| Monoisotopic Mass | 591.20172853 g/mol |
| Topological Polar Surface Area | 119 Ų |
| Heavy Atom Count | 42 |
| Formal Charge | 0 |
| Complexity | 901 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 1 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Multi-mode Kinase Inhibitor EOC317 is an orally available, small molecule, multi-mode kinase inhibitor (MMKI), with potential antineoplastic activity. Upon oral administration, MMKI EOC317 targets, binds to and inhibits the activity of a variety of kinases, such as phosphatidylinositol 3 kinase (PI3K), and the receptor tyrosine kinases, fibroblast growth factor receptor (FGFR), angiopoietin-1 receptor (TIE 2), and vascular endothelial growth factor receptor-2 (VEGFR-2). This inhibition may result in an induction of apoptosis of susceptible tumors cells in which these kinases are overexpressed.